Stocks · News reference
5 Earnings Losers With More Downside Ahead
It’s been a generally successful earnings season for most of the market, as EPS figures remain strong and analysts continue to raise estimates. But not everyone is joining the party. Earnings reports from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Maintains Overweight on AppLovin, Lowers Price Target to $450
Morgan Stanley analyst Matthew Cost maintains AppLovin (NASDAQ:APP) with a Overweight and lowers the price target from $650 to $450.
Jim Cramer Recommends Buying This Communication Services Stock, Calling It ‘Amazing’
Cramer backs Sphere and Cameco, urges selling AppLovin, criticizes Honeywell and QXO, and sees limited-risk upside in Aflac.
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.
Altria (MO) Advances While Market Declines: Some Information for Investors
Altria (MO) outperformed the broader market on September 14, 2026, closing up 2.4% while the S&P 500 declined 0.48%. The stock has gained 4.99% over the past month. Upcoming Q3 earnings are expected on October 29, 2026, with projected EPS of $1.5 (up 3.45% YoY) and revenue of $5.33 billion (up 1.49% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 12.16, trading at a discount to its industry average of 14.21.
Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food
President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.